Literature DB >> 2154054

Disseminated intravascular coagulation after hepatic resection.

T Tsuzuki1, K Toyama, K Nakayasu, S Iida, M Ueda, A Toizumi.   

Abstract

Disseminated intravascular coagulation (DIC) after hepatic resection is a serious complication that leads to a fatal outcome unless prompt treatment is instituted. Between April 1973 and June 1988, DIC occurred postoperatively in 18 of 192 patients who underwent hepatic resection because of a variety of diseases of the liver and biliary tract. The diagnosis was made on the basis of changes in platelet count, fibrinogen level, serum level of fibrin degradation product (FDP), and protamine sulfate test. Heparin was used in an earlier series but has been discontinued because of difficulty in determining the optimal dose in patients undergoing liver resection. Instead, we now use gabexate mesilate, which blocks the coagulation cascade without the aid of antithrombin III and works as an anticoagulant. Fifteen patients had uneventful recoveries, but three died. Two died of aggravation of DIC, which was a result of reoperation performed under the diagnosis of surgical bleeding. The other patient died of liver failure after fever of unknown cause persisted for 4 months. The rationale for the diagnosis and treatment of DIC after liver resection is documented, and the problems involved are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154054

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  2 in total

Review 1.  Drugs to facilitate recovery of neuromuscular blockade and muscle strength.

Authors:  Yuhji Saitoh
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

2.  Colorectal liver metastasis surgery: analysis of risk factors predicting postoperative complications in relation to the extent of resection.

Authors:  Ralf Konopke; Stephan Kersting; Alfred Bunk; Janine Dietrich; Axel Denz; Jörg Gastmeier; Hans-Detlev Saeger
Journal:  Int J Colorectal Dis       Date:  2009-02-13       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.